Symbols

RANI

Rani Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

Gap Down

EPS Beats Expectation

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RANI

Rani Therapeutics Holdings, Inc.

A clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs

Industry

Pharmaceutical

Established Date

04/06/2021

Listing Date

07/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ranitherapeutics.com

Security Type

Common stock

Office address

2051 Ringwood Avenue, San Jose, California 95131

Business

Introduction

Rani Therapeutics Holdings, Inc., was incorporated in Delaware on April 6, 2021. The company is a clinical-stage biotherapeutic company advancing technology to facilitate the development of oral biologics, which the company believes has the potential to transform medicine and improve treatment outcomes for patients. The company developed RaniPill capsules, the company's novel, proprietary and patented platform technology designed to replace subcutaneous or intravenous biological agents with oral administration.

Company Financials

EPS

RANI has released its 2025 Q4 earnings. EPS was reported at -0.07, versus the expected -0.05, missing expectations. The chart below visualizes how RANI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RANI has released its 2025 Q4 earnings report, with revenue of 1.46M, reflecting a YoY change of 42.12%, and net profit of -9.07M, showing a YoY change of 42.28%. The Sankey diagram below clearly presents RANI's revenue sources and cost distribution.